FAQ: Pharmacist Understanding of mRNA Vaccine Technology

As frontline immunizers navigate evolving clinical guidance and heightened patient hesitation, understanding the scientific platform and effective communication tools to deliver mRNA vaccination has become essential for today’s pharmacy practice.

“Debate surrounding the technology intensified during the COVID-19 pandemic because of the rapid pace of vaccine development and emergency use authorization,” Darren Mensch, PharmD, BCPS, BCACP, clinical ambulatory care pharmacist of population health at Jefferson Health and vaccination expert, told Drug Topics®. “Widespread misinformation regarding vaccine safety, manufacturing timelines, and how mRNA vaccines work, in addition to limited public understanding of how these vaccines differ from traditional vaccines, contributed substantially to vaccine hesitancy.”

Among the most accessible and trusted frontline health care professionals, pharmacists occupy a unique position in modern preventative care. The rapid emergence and public debate surrounding mRNA technology have transformed routine vaccination conversations into pivotal clinical encounters.

Navigating this shifting landscape requires a dual understanding of core platform mechanics and structured communication strategies. Amid fragmented national vaccine guidance and expanding applications beyond seasonal respiratory illnesses, pharmacy professionals need practical, evidence-based insights at their fingertips.

Read through Mensch’s insights as he provides a detailed look into why mRNA vaccines are becoming a standard in preventative care, what the debates are surrounding the technology, and how pharmacists can meander hesitancy at the pharmacy counter.

READ MORE: FAQ: What the RFI on Vaccine Categories Means for Pharmacists

What is mRNA vaccine technology and why has it stirred up such heated debates across health care in recent history?

Messenger RNA (mRNA) vaccines are a class of vaccines that use laboratory-produced mRNA to instruct the body’s cells to make a specific antigen, prompting both antibody and cellular immune responses.¹

Debate surrounding the technology intensified during the COVID-19 pandemic because of the rapid pace of vaccine development and emergency use authorization. Widespread misinformation regarding vaccine safety, manufacturing timelines, and how mRNA vaccines work, in addition to limited public understanding of how these vaccines differ from traditional vaccines, contributed substantially to vaccine hesitancy.

How new or novel is the pharmaceutical industry’s understanding of this clinical technology?

Although widespread use of mRNA vaccines is recent, the underlying science has been studied for decades. Early development was limited by the instability of synthetic mRNA and its tendency to trigger a strong innate immune response.

A major breakthrough came in 2005, when researchers showed that modified nucleosides could reduce inflammatory recognition by toll-like receptors. This discovery, together with advances in lipid nanoparticle delivery, laid the foundation for the effective mRNA vaccine platforms used today.²

How does mRNA technology differ from the traditional vaccines that have been administered for decades?

Traditional vaccines expose the immune system to an antigen by using a weakened or inactivated pathogen, a protein component, or another non-mRNA platform. In contrast, mRNA vaccines contain no infectious virus. They deliver temporary genetic instructions that enable the body’s cells to produce a target antigen and stimulate an immune response.

The mRNA does not enter the cell nucleus or alter DNA, and it is naturally broken down after delivering its instructions. Because mRNA vaccines can be designed and manufactured without growing large quantities of a pathogen, the platform may allow faster development and more adaptable production.

However, safety and effectiveness depend on the specific vaccine, disease, and available clinical evidence.

What are the key approaches pharmacists can take if patients present with concerns regarding acceptance of an mRNA vaccine?

Among the most accessible, trusted frontline health care professionals, pharmacists can help patients make informed vaccine decisions by listening to their concerns, asking open-ended questions, and responding with clear, evidence-based information tailored to each patient’s needs and risk factors.

One practical, evidence-based communication strategy from the Trusted Messenger Program (TMP) is the AIMS approach:

• Announce: Offer a friendly, confident, and matter-of-fact recommendation to get the vaccine.
• Inquire: Listen actively and ask open-ended questions to understand patients’ concerns.
• Mirror: Reflect and validate their perspectives in their own words with empathy.
• Secure: Ask permission to provide additional information and support the patient, even if they initially decline the vaccine.

This approach can help pharmacists build trust and support informed vaccine decision-making.

This video provides additional explanation and examples: The AIMS Approach to Vaccine Conversations.

With the current fragmentation and inordinance regarding national vaccine guidance, what role will mRNA technology play in the near- to long-term future regarding the vaccine delivery space?

Building on the clinical success of COVID-19 vaccines, mRNA technology is likely to remain an important platform for vaccine research and development. Its relatively rapid development cycle and adaptability may support vaccines against additional infectious diseases and emerging pathogens, although future use will depend on disease-specific evidence of safety, effectiveness, durability, feasibility, and public acceptance.

Currently, there are numerous mRNA vaccines for COVID-19, and there are also mRNA vaccines for both influenza and respiratory syncytial virus (RSV).

Beyond preventive vaccines, researchers are also evaluating mRNA-based approaches for personalized cancer vaccines and other immunotherapies. These applications remain at different stages of clinical development and will require continued evaluation.

Conclusion

Looking ahead, mRNA technology will continue to reshape the immunization landscape, extending into novel combination vaccines and therapeutic platforms. Yet, regardless of how advanced the underlying biotechnology becomes, the human element at the pharmacy counter remains the vital bridge between scientific innovation and public health acceptance.

By pairing rigorous platform knowledge with empathetic, evidence-based communication strategies, pharmacists can effectively dispel misconceptions and foster long-term patient trust.

READ MORE: Immunization Resource Center

REFERENCES

1. Gote V, Bolla PK, Kommineni N, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):2700. doi:10.3390/ijms24032700

2. Karikó K, Buckstein M, Ni H, et al. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165-175. doi:10.1016/j.immuni.2005.06.008